Alyson Smith
Vice President, Research Callio Therapeutics
Alyson Smith currently serves as the Executive Director of Biology at Callio Therapeutics, where she oversees preclinical ADC programs. With more than two decades of experience across biopharma, Alyson previously held senior roles at Pfizer, Seagen and Inimmune. Alyson was also an assistant research professor at the University of Montana and a postdoctoral scientist at GlaxoSmithKline and Mayo Clinic.
Alyson received her PhD in Molecular Pharmacology and Experimental Therapeutics from the Mayo Clinic Graduate School of Biomedical Sciences and her BSc in Molecular Biology and Chemistry from the University of Wyoming.
Seminars
Tuesday 13th October 2026
Panel Discussion: What’s the New Path to the Next Generation of ADCs?
3:30 pm
- Understanding how to migrate from non-selective ADC payloads
- Debating the right properties for a next-generation payload and linker: Can (or should?) any small molecule therapeutic be developed into an ADC?
- Debating the right strategy for dual payload ADCs
- Understanding ADC toxicity and developability for next generation conjugates
Wednesday 14th October 2026
Leveraging a Modular & Adaptable Linker Design to Evaluate Translation of Rationally Selected Dual Payload Combinations
12:00 pm
- Developing a modular and adaptable linker design to allow rapid production of a wide range of dual payload ADCs
- Designing a preclinical framework to give confidence in translation of efficacy and safety of dual payload ADCs against different targets
- Utilizing approach to derisk the development of a pipeline of dual payload ADCs focusing on CLIO-8221 and CLIO-84XY
